INTRODUCTION
Despite dramatic improvement in acute care of spinal cord injury (SCI), recovery due to repair of severed neuronal pathways has not been achieved. Intraspinal neural grafting is considered to be a potential treatment of clinical SCI because fetal spinal cord transplants have proven effective in enhancing locomotion recovery in experimental models (7, 8, 14, 15, 42, 63, 64) . However, fetal transplants entail biological and ethical problems that are likely to limit their use. It is presently difficult to genetically modify primary fetal tissue or to assure its uniformity. Neural stem cells or multipotent progenitors may circumvent some of these limitations. Engraftable lines of neural stem cells or progenitors may be propagated by a number of genetic or epigenetic means (reviewed in 66). Among the most effective and safe means of generating stable neural stem cell clones has been via retrovirus-mediated gene transfer of propagating genes, such as v-myc (50) and SV40 large T-antigen, which allowed isolation of neural stem cells from newborn mouse cerebellum (50, 55) , embryonic rat hippocampus (48) , embryonic rat striatum (11) , and embryonic rat medullary raphe (65, 67) . Stable self-renewing, multipotent, clonal stem cell lines are attractive for CNS gene transfer studies because they are readily genetically modified ex vivo by standard retroviral techniques and can stably express transgenes robustly in vivo following transplantation (34, 58) . Genetically modified neural progenitor or stem cells have been shown to ameliorate experimental brain diseases by complementing enzymatic deficiency, providing neurotrophic support, or replacing missing neural cells (3, 27, 35-39, 49, 56-60, 62) . Their potential for treating SCI seems promising, but has received little study (16) . Primary skin fibroblasts, genetically modified to produce neurotrophin-3 (NT-3), have been shown to promote corticospinal tract regeneration and locomotion recovery following SCI (21) . However, fibroblasts cannot replace missing neural elements. We hypothesized that neural stem cells producing NT-3 might prove even more attractive than fibroblasts because of their additional ability to differentiate into neural phenotypes. C17.2 is a clone of neural stem cells which has proven a very useful model for elucidating the therapeutic potential of this cell type (reviewed in 57). C17.2 cells proliferate and can differentiate into neurons, oligodendrocytes, and astrocytes in vitro and in vivo (26, 50, 55, 66) . The cells mediated the transfer of many therapeutic genes including those needed to treat such neurodegenerations as the lysosomal storage diseases Sly disease (58) and Tay-Sachs disease (27) . C17.2 is the lacZ-expressing subclone of a parent neural stem cell clone named C17. In the first part of this report we describe the genetic modification of clone C17 cells by retroviral-mediated gene transfer of an NT-3.IRES.GEO gene (see below). The NT-3-expressing neural stem cells, designated C17.NT-3, were then characterized in vitro.
Despite the success of xenografting in a variety of CNS disease models (2, 4, 5, 45, 52) , the feasibility of xenografting genetically modified neural stem cells to treat SCI has received little attention. In the second part of this study, we xenografted C17.NT-3 cells into intact spinal cord of adult Sprague-Dawley rats immunosuppressed with cyclosporin A (CsA) and studied their survival, differentiation, and transgene expression.
METHODS

Preparation of the Retrovirus Vector and the Packaging Cell Line
A retroviral construct encoding the NT-3.IRES.GEO sequence was prepared using the LIG vector (provided by Dr. L. Lillien) and a 850-bp fragment of the human NT-3 cDNA containing the coding region (provided by Dr. L. Reichardt). The NT-3 fragment was isolated by digestion with NotI-EcoRV restriction enzymes and subcloned into the NotI-SnaBI sites of LIG as shown in Fig. 1 . The resulting vector, which was named LIG/ NT-3, contains a human NT-3 gene, an encephalomyocarditis virus (EMCV) internal ribosomal entry site (IRES), and a GEO gene which is a fusion gene of the lacZ (encoding Escherichia coli ␤-galactosidase) and neomycin resistance (neo) genes. The entire NT-3.IRES.GEO sequence is driven by the Rous sarcoma virus (RSV) long terminal repeat (LTR) and is transcribed as a multicistronic mRNA. The IRES directs cap-independent translation of the mRNA by providing internal binding sites for ribosomes and ensures efficient coexpression of the NT-3 and GEO genes (20, 24, 25, 43) . The vector was used to transfect the packaging cell line 2 (33, 41) , and neomycin-resistant clones were selected in the presence of 600 µg/ml of G418 (GIBCO). High titers [10 6 colony-forming units (cfu)/ml] of replication-incompetent retrovirus were obtained from the producer cells. Clones ( 2 -NT-3) that produced the highest viral titer were propagated and stored. Both the producer cells and their conditioned media were analyzed by Western blotting to verify the production of NT-3 protein (see below).
Constructing the Genetically Modified Neural Stem Cell Line (C17.NT-3)
The C17 neural stem cell clone was initially isolated from newborn mouse cerebellum and propagated by retroviral vector-mediated transduction of the propagating gene v-myc, which interacts with cell cycle regulatory proteins. Clone C17.2 is a subclone with a retrovirus encoding lacZ. Both retroviral vectors also contained neo driven by an internal SV40 promoter. Since C17.2 cells contain both neo and lacZ genes, it was difficult to select transduced clones using either marker encoded by the LIG/NT-3 virus. Consequently, the C17.2 cells were modified with a retrovirus that contained the alkaline phosphatase reporter gene (LIA, provided by Dr. L. Lillien) and rat NT-3 cDNA (provided by Dr. M. Tessier-Lavigne). Since the parental clone C17 contains only the neomycin resistance gene, it was possible to The rate of NT-3 production by C17.NT-3 cells was measured using a slot blot assay (B). Samples 1-5 are recombinant human NT-3 loaded at concentrations of 2 µg/ml, 400 ng/ml, 80 ng/ml, 16 ng/ml, and 3.2 ng/ml, respectively. Samples a-c are conditioned media from unmodified cells (a) and C17.NT-3 cells that have been cultured for 2 months (b) and 1 week (c). Both cultures of genetically modified cells secrete NT-3 at a rate of about 90 ng/10 6 cells/24 h. The biological activity of secreted NT-3 was analyzed using an E8 chick DRG assay. Both recombinant human NT-3 (E) and conditioned medium (D) from the producer cells induced neurite outgrowth from the DRG neurons, whereas conditioned medium from unmodified cells induced no outgrowth (C). Bar, 500 µm.
Cell Culture
The C17 and C17.2 cells, as well as their derivatives C17.NT-3 and C17.2.NT-3 cells, were cultured in a standard medium (50) which contains DMEM ϩ 10% FCS ϩ 5% HS ϩ 2 mM glutamine. For surgery or stock, the cells were grown on 100-mm uncoated tissue culture dishes (Falcon) and split weekly at 1:20 ratio into fresh medium. For in vitro histochemical and immunocytochemical staining, cells that were grown to near confluence on a 100-mm culture dish were trypsinized, 10% of the cells harvested were resuspended in 5 ml of growth medium, and 450 µl of cell suspension was seeded into each chamber of uncoated or poly-Lornithine-coated eight-chamber LabTek glass slides (Nunc) and cultured for 3-4 days. Unless specified, all reagents were purchased from GIBCO. The 2 -NT-3 producer cell line was maintained in DMEM ϩ 10% CS ϩ 2 mM glutamine ϩ 10,000 units/ml penicillin and streptomycin.
Preparation of Cells for Transplantation
On the day of surgery dishes containing 90% confluent cells were washed three times with Hanks' balanced salt solution (HBSS), trypsinized, gently triturated, counted, washed, pelleted (900 rpm for 5 min), and resuspended in growth medium at a concentration of 10 5 cells/µl. Cell viability was shown by trypan blue (Sigma) stain to be greater than 80-90% prior to surgery. The cells were maintained on ice during surgery. After surgery, part of the remaining cells were stained with trypan blue and the rest were replated and stained by X-gal histochemistry to confirm viability and transgene expression. Usually, greater than 70-80% of the cells remained viable and X-gal staining remained robust.
Western Blotting and Slot Blotting Analysis of Transgene Expression
To verify NT-3 expression by the 2 -NT-3 producer cells, immunoblotting with polyclonal anti-NT-3 antibody (Promega) was carried out according to the procedure previously described (30) . Briefly, the day before harvest, confluent 2 -NT-3 cells grown on 24-well plates (Falcon) were washed with HBSS, and 500 µl of DMEM (serum free) was replenished in each well. The cells were cultured for an additional 24 h. The medium was then collected and mixed with an equal volume of 2ϫ sample buffer (125 mM Tris, 4% SDS, 20% glycerol, 10% 2-mercaptoethanol, pH 6.8). The cells were gently scraped off and homogenized with a Teflon-glass homogenizer in 5 vol of homogenization buffer [50 mM Tris (pH 7.5), 2 mM EDTA, 1 mM PMSF, 25 mM leupeptin, 1.0% aprotinin]. The homogenate was centrifuged at 15,000g for 10 min at 4°C. The supernatant was then mixed with an equal amount of 2ϫ sample buffer. Samples containing medium or cell homogenates were loaded onto adjacent lanes and separated by 10% SDS-PAGE and then transferred onto nitrocellulose (NC) membranes and processed for Western blotting. The NC membranes were first incubated with 5% nonfat dry milk in TTBS buffer (0.1% Tween 20, 150 mM NaCl, 50 mM Tris-HCl, pH 7.6) for 1 h followed by overnight incubation with primary antibodies for NT-3 reagents (Amersham). The specificity of the antibody was verified by probing control 2 cells under identical conditions. For slot blot analysis recombinant human NT-3 and samples of conditioned medium (100 µl) were applied onto NC membrane with a slot blot apparatus, dried overnight, and processed for immunostaining with the NT-3 antibodies as described for the Western blot.
NT-3 Bioassay
Conditioned media from 2 -NT-3 producer cells and control cells were tested for the production of bioactive NT-3 using an E-8 chicken DRG explant bioassay. Briefly, confluent cultures of cells were split onto 50-mm culture dishes at 1:3 ratio (Becton Dickinson Labware) and cultured for 24 h. On the second day, the cells were washed three rinses with HBSS and fed with low serum (0.1% FCS) medium. The cells were then cultured for an additional 24 h, and conditioned media were collected for bioassay. Fertile eggs (SPAFAS, Preston) were incubated in a humidified incubator at 37°C for 8 days before use. E8 embryos were removed into a sterile petri dish containing prewarmed (37°C) DMEM with 0.1% heat-inactivated goat serum and lumbar DRG were gently dissected out and embedded in a 12-well culture plate containing 600 µl of collagen gel which was prepared by mixing solutions A (CH 3 COOH containing 0.3% rat tail type I collagen, Upstate Biotechnology, Lake Placid, NY), B (10ϫ DMEM), and C (2.2 g NaHCO 3 , 4.77 g Hepes in 100 ml 0.05 N NaOH) at a ratio of 4:1:1. Three DRGs were placed into each well of the 12-well plates, and the gel solution was allowed to solidify by incubating at 37°C for 20 min. Conditioned culture medium (400 µl) was then applied onto wells containing the DRG explants. The conditioned media were used without dilution or diluted at 1:2 and 1:10. Neurite outgrowth from the DRG was examined at 24-48 h and compared with 15, 45, and 450 ng/ml recombinant human NT-3.
Surgical Procedure and Tissue Preparation
Forty-one female Sprague-Dawley rats (200-250 g; Taconic, Germantown, NY) were studied. All procedures were approved by the institutional animal welfare committee and followed the NIH guidelines for the care and use of laboratory animals. Thirty-three animals received C17.NT-3 cell transplants and were euthanized at 1 week (n ϭ 11), 2 weeks (n ϭ 8), 4 weeks (n ϭ 7), or 8 weeks (n ϭ 7). Eight animals received C17.2 cell transplants and were euthanized at 1 (n ϭ 5) and 2 weeks (n ϭ 3). Rats were anesthetized with an intraperitoneal (ip) injection of acepromazine maleate (0.7 mg/kg), ketamine (95 mg/kg), and xylazine (10 mg/kg) and underwent laminectomy at the T7-T8 level to expose one spinal cord segment, and then 5 µl of cell suspension (10 5 cells/µl) was injected into the center of spinal cord with a 10-µl Hamilton syringe attached to a glass pipet (tip diameter 50 µm). The needle was held in place for about 1 min and gradually withdrawn; the injection site was labeled with a 10-O silk suture through the dura. At each survival time shown in Table  II , animals were anesthetized with an ip injection of sodium pentobarbital (100 mg/kg) and perfused with 200 ml of normal saline followed by 500 ml of ice-cold 4% paraformaldehyde in 0.1 M phosphate buffer (pH 7.4). The region of spinal cord containing the graft was identified by the suture. A spinal cord tissue block (approximately 2 cm in length) containing the graft was then dissected out and immersed in 0.1 M phosphate buffer (PB) at 4°C overnight followed by cryoprotection in 30% sucrose (in 0.1 M PB containing 0.5 mM Thimerosal) for 2 days. Tissue was then embedded in OCT compound (Fisher Scientific) and cut into 20-to 40-µm-thick longitudinal sections on a cryostat.
Histology and Immunocytochemistry
X-gal histochemical and immunocytochemical staining procedures were described before (28) . Table I summarizes the primary antibodies used in the study. The fluorescent secondary antibodies, including fluorescein (FITC) conjugate donkey anti-rabbit IgG(H ϩ L), Texas red conjugate donkey anti-rabbit IgG(H ϩ L), FITC conjugate goat anti-mouse IgG ϩ IgM, and Texas red conjugate goat anti-mouse IgG (H ϩ L), were purchased from Jackson Immunochemicals. The DAB reactions were carried out using the Vectastain ABC kit (Vector Labs Inc.).
Immunosuppression with CsA
Oral CsA solution (Sandoz Pharma Ltd.) was administered via the drinking water (50 µg/ml) starting 3 days before surgery and throughout the postoperative period.
Image Analysis
Images were captured using a Photometric Sensys KAF-1400 CCD camera (Photometric Inc.) and a DAGE color video camera attached to a Leica DMRBE microscope and processed on a Macintosh Power PC 8500 b Numerator, number of animals with grafts in the group; denominator, total number of animals in the group. 
RESULTS
Part I: Constructing the NT-3-Producing Neural Stem Cells (C17.NT-3)
The retroviral vector LIG/NT-3 encodes three genes that are essential for this experiment (Fig. 1) . NT-3 is the gene of principal interest; ␤-gal and neomycin resistance genes are selection markers that were utilized to select out the packaging cell line ( 2 -NT-3) and the NT-3 expressing stem cell line (C17.NT-3). The neo gene rendered the transfected 2 cells resistant to the antibiotic G418 and allowed several G418-resistant clones to be isolated. As shown in Fig. 2 , conditioned media obtained from two clones of packaging cells (NT-3-#16 and NT-3-#21) contained high levels of NT-3 which was detected using a polyclonal antibody in Western blot ( Fig. 2A, lanes 2 and 3) . NT-3 was also detected in 2 -NT-3 cell homogenates (data not shown). In contrast, virtually no NT-3 protein was detected in either nontransfected 2 cell homogenates or the media conditioned by them (Fig. 2, lane 1) . The biological activity of secreted NT-3 was analyzed using a standard E8 chick DRG assay. As shown in Figs. 2C-2E, both conditioned medium from NT-3 producer cells and recombinant human NT-3 induced neurite outgrowth from E8 chick DRG, whereas medium from control unmodified cells induced no neurite outgrowth. These data indicate that the engineered producer cells actively synthesize and secrete biologically active NT-3 protein.
Because C17 cells contain the neomycin resistance gene (50), we used the ␤-gal gene to screen the LIG/NT-3-transduced C17 cells. The 2 /NT-3 packaging cells produce high titers of LIG/NT-3 virus (10 6 cfu/ml), which allowed efficient infection of the C17 cells. After two rounds of selection using limiting dilution, three clones (E12, D6, and A11) were obtained that contained virtually 100% X-gal-positive cells. These clones were propagated and banked. At each stage of propagation and freezing, the uniformity of the cell lines was examined by X-gal staining. By the time that enough cells had been grown for storage, 90-95% of the cells were X-gal positive. The E12 clone, which contained at least 95% X-gal-positive cells at early passages, was named C17.NT-3 and used in the present study. Figures  3A and 3B shows the X-gal histochemical staining of a culture of C17.NT-3 cells. At low magnification (Fig. 3A) almost all the cells appeared X-gal positive (A). At higher power (Fig. 3B, arrowheads) , a few X-galnegative cells were found intermingled with the X-galpositive cells. In order to determine whether C17.NT-3 cells expressed NT-3, we double stained the X-galpositive cells with the NT-3 antibody. X-gal-positive cells were blue (Figs. 3A-3D ), NT-3-positive cells were brown (Figs. 3C and 3D) , and cells coexpressing lacZ and NT-3 genes were green (Figs. 3C and 3D) . A majority of C17.NT-3 cells (85%) expressed both NT-3 and lacZ genes (Fig. 3C) . About 10% expressed only NT-3, less than 5% expressed only lacZ, and less than 1% expressed neither gene (Fig. 4) . In contrast, control C17 cells showed no X-gal staining. C17.2 cells were 100% X-gal positive. Both C17 and C17.2 cells express low levels of NT-3 intrinsically, which were substantially augmented by transduction with the NT-3-encoding retrovirus (46) . The rate of NT-3 production by C17.NT-3 cells was measured using a slot blot assay: this was estimated to be 90 ng/10 6 cells/24 h and remained at the same level for cells that were cultured for at least 2 months (Fig. 2B ).
Part II: In Vitro Characterization of C17.NT-3 Neural Stem Cells
We examined the phenotype of C17.NT-3 cells under normal growth conditions (DMEM ϩ 10% FCS ϩ 5% HS ϩ 2 mM glutamine). C17.NT-3 cells grew rapidly on uncoated LabTek glass slides. With 1:20 split ratio, cells reached confluence in about 1 week. During rapid growth the cells assumed a flat fibroblastic appearance (Fig. 5B) , as previously described (50, 55) . At confluence, the cells displayed contact inhibition without piling up or forming clusters. When stained with antibody for nestin, an intermediate filament expressed in undifferentiated neuroepithelial stem cells (12, 13, 48) , all the C17.NT-3 cells were nestin positive (Figs. 5A, 5C, and 5E). The cells were unreactive for specific markers for neurons (MAP2, MAP1B), astrocytes (GFAP), or oligodendrocytes (O1, RIP). Because substrates can influence in vitro differentiation of C17 cells (50, 55), we grew the C17.NT-3 cells on poly-L-ornithinecoated LabTek glass slides. After 3-4 days in culture, C17.NT-3 cells began to demonstrate more differentiated morphologies (Figs. 5C and 5E ), but these proliferative, still incompletely differentiated cells remained nestin positive and did not express the cell-specific antigens for neurons (MAP1B; Figs. 5C and 5D) or astrocytes (GFAP; Figs. 5E and 5F). A small percentage of cells began to express an oligodendrocyte marker (O1, Figs. 5G and 5H ). C17.NT-3 cells remain in an incompletely differentiated progenitor stage if maintained in the cell cycle. In contrast, control untransduced C17 cells appear bipolar on uncoated or poly-Lornithine-coated plates and spontaneously differentiate into neurons or glia much more quickly and exhibit phenotype drifting under growth conditions (50, 55) .
To determine whether the relative in vitro phenotype stability of the C17.NT-3 cell line was due to the effect of NT-3 expression, we compared the C17.NT-3 cell line to another NT-3 producing subclone of C17 (C17.2.NT-3) which we constructed from the lacZ-expressing subclone of C17 called C17.2 (22, 46, 55, 58) . In contrast to C17.NT-3, C17.2.NT-3 cells are bipolar or multiprocessed during the growth phase and at confluence, as is characteristic of C17.2 cells (55) . In addition the expression of NT-3 induced spontaneous differentiation of C17.2.NT-3 cells. Most C17.2.NT-3 cells expressed MAP1B, a neuronal marker (Figs. 6B and 6C); many of them also expressed the neuronal marker MAP2 (Fig.  6A ). These observations are in accordance with a previous report by Park et al. (46) , which found that nearly 90% of C17.2.NT-3 cells expressed neurofilaments. Directing neural stem cells to differentiate toward a specific lineage may increase their attractiveness as transplants because an enriched neuronal precursor population may replace lost neurons and reestablish neuronal connectivity. The differences between the two NT-3-expressing subclones suggest variations that may relate to retroviral insertion site factors or other intrinsic changes.
Part III: Intraspinal Xenografting of C17.NT-3 Cells
We compared intraspinal transplants of C17.NT-3 and C17.2 cells. C17.2 cells have been shown to differentiate into neurons or glia and integrate in a cytoarchitecturally appropriate manner when allografted into neonatal or adult mice (27, 49, 55, 57, 58, 60, 66) . Table II summarizes the survival of clone C17.NT-3 and clone C17.2 at different postoperative times. At 1 and 2 weeks, the survival of both clones was comparable. Short-term animals tended to have the largest grafts (Fig. 7) , with cells densely accumulated in the injection site (Figs. 7A and 7B ) and vascularization by the host within 1 week (Fig. 7A) .
The engrafted C17.NT-3 cells also expressed both transgenes as demonstrated by X-gal histochemistry (Figs. 7C and 7D ) and by immunocytochemistry with anti-␤-gal (Fig. 7E) and anti-NT-3 antibodies (Figs. 7F  and 7G ). X-gal/␤-gal-positive cells were usually found on the periphery of the graft, whereas cells in the center were negative (Figs. 7C-7E ). At the host-transplant interface, C17.NT-3 cells (Fig. 7D) were integrated with host cells (Fig. 7D) as if migrating out of the transplant. As under culture conditions, C17.NT-3 cells coexpressed the ␤-gal and NT-3 genes (Figs. 7F and 7G) . The number of cells that were X-gal/␤-gal positive rapidly decreased with time. This decrease, together with the intermingling of grafted cells with the host, made assessment of graft size difficult. However, X-gal/ ␤-gal-positive cells with clear neuronal or glial morphologies remained among the host cells at 2 months (Fig. 8E) .
Morphology and phenotype marker expression indicated that C17.NT-3 cells differentiated into both neurons and glia. In contrast to their appearance in vitro (Fig. 5) , many C17.NT-3 cells assumed a spindleshaped morphology in vivo (Fig. 8A) . Some differentiated, became bipolar or multipolar, and had long processes (Fig. 8) . A small percentage of these cells demonstrated a clearly neuronal morphology (Figs. 8B,  8D , and 8E). Fewer cells showed a glial morphology (Figs. 8D and 8E ) and some cells appeared undifferentiated (Fig. 8B) . Figure 9 shows double-label immunocytochemistry with anti-␤-gal antibody and antibodies specific for neurons (MAP1B, Figs. 9A and 9B), astrocytes (GFAP, Figs. 9C and 9D ), or oligodendrocytes (RIP, Figs. 9E and 9F ). More cells expressed neuronal markers than glial markers in accordance with our morphological observations, but most of the ␤-galpositive cells expressed neither marker and remained nestin positive (data not shown). This result suggests that they remained quiescent, incompletely differentiated, or uncommitted neural stem cells or progenitors. X-gal/␤-gal-positive cells sometimes overlapped with intense RIP staining, but we found no double-labeled cells (Figs. 9E and 9F) . The RIP staining appeared fiber-like, resembling myelinated axons (Fig. 9F , arrowhead) rather than processes characteristic of C17.2 cell grafts. NT-3 expression by C17.NT-3 cells may therefore induce host myelinated axons to penetrate the graft. Alternatively, differentiation of neural stem cells toward a neuronal lineage, as promoted by NT-3, may in turn promote enhanced differentiation and myelination by oligodendrocytes, consistent with some hypotheses on oligodendrocyte differentiation (40) . 
C17.NT-3 cells also demonstrated migratory activity.
In all animals that contained a graft, some engrafted cells migrated for variable distances within the host spinal cord. Within 1 week, some cells had migrated at least 1 cm from the injection site (Fig. 10) , and some had migrated even further along the central canal (data not shown). In all animals, cells that were ectopic to the injection site generally assumed one of two different morphologies. Most appeared undifferentiated with round soma and no processes ( Fig. 10A; Fig. 8B,  arrowheads) , but a small percentage showed a more mature morphology (Fig. 10B) . We speculate that C17.NT-3 cells may migrate in an undifferentiated form and then stop migration, differentiate, and integrate into the host tissue when they encounter the proper host environment. Engrafted cells continued to migrate throughout the survival period; by 2 months the grafts appeared smaller and ␤-gal-positive cells were integrated into host parenchyma (Fig. 8E) . However, since the number of engrafted cells varied dramatically in animals at different time points, probably due to immune rejection and reporter gene downregulation, we did not quantify the percentage of cells that had migrated away from the initial graft site.
The effect of in vivo NT-3 production on the host spinal cord was studied using a neurofilament antibody RT-97. Grafts of C17.NT-3 cells induced profuse axon ingrowth from host spinal cord (Figs. 11A and 11B) , whereas no RT-97-immunoreactive profiles were present in the C17.2 grafts (Figs. 11C and 11D) .
Despite oral immune suppression with cyclosporin, there was a host immune response to the xenografts. The center of the graft, where cells were ␤-gal negative, was filled with densely labeled OX-42-positive cells (Fig. 12A) , suggesting invasion by macrophages. A robust astrocyte activation surrounded the grafts (Fig.  12B) .
In control animals, at 1 and 2 weeks, engrafted C17.2 cells demonstrated comparable survival, differentiation, migration, and ␤-gal expression as C17.NT-3 cells, but, as expected, no X-gal-positive cells were double labeled by NT-3 antibody (data not shown).
DISCUSSION
The data from the present study demonstrate the feasibility of using genetically modified neural progenitor and stem cells to deliver neurotrophins such as NT-3 into the spinal cord.
Pros and Cons of the LIG/NT-3 Retroviral Vector
Several features make the LIG/NT-3 retrovirus construct a useful vector for genetically modifying neural stem cells as represented by clone C17. First, the vector encodes two selection markers (neo and ␤-gal) which enabled convenient selection of the packaging cell line ( 2 -NT-3) and the NT-3-expressing neural stem cell clones (C17.NT-3). Second, the combination of LTR promoter and IRES allowed high levels of coexpression of NT-3 and selection marker genes both in vitro (85%) and in vivo (Figs. 3C and 3D, 4 , and 7F and 7G). A previous study using lacZ.IRES.CAT and lacZ.IRES.vSrc retroviral vectors (20) found IRES to be superior to internal promoter or regulated splicing vector strategies because it ensured stable coexpression (Ͼ90%) of lacZ/CAT or lacZ/v-Src under in vitro or in vivo conditions. Third, the ␤-gal marker permits convenient detection of transplanted cells with histological and immunological methods, both at the cellular and at the ultrastructural levels (44, 49, 53, 55) . Labeling of transplanted cells also appears to be specific because recycling of ␤-gal among host cells such as macrophages or microglia has not been reported. In contrast, recycling by host cells is an important consideration (31, 32) . ␤-gal labeling is therefore unlikely to overestimate transplant survival, but some characteristics of the grafts may cause survival to be underestimated. For example, several studies that used a viral promoter to drive ␤-gal expression have observed downregulation of the promoter, especially after postoperative intervals longer than 1 month (28, 29, 54) . The site at which the retrovirus integrates its DNA into the host genome and the differentiation state of the neural stem cells may also contribute to an underestimation of survival of donor-derived cells labeled with ␤-gal. Another possibility is migration of the cells from the graft. We observed ␤-gal-positive cells located more than 1 cm from the graft at 1 week, and similar observations have been reported for neural stem cell lines allografted into adult rat striatum (32) . Reduction in donor cell number may also be due to immunological elimination of cells expressing the foreign ␤-gal transgene. One or more of these mechanisms may account for the fewer donor-derived cells that we observed at later survival times.
In Vitro and in Vivo Transgene Expression in C17-NT-3 Cells
The stability of transgene expression by C17.NT-3 cells in vitro is shown by the staining intensity and the large number of stained cells that we found in longterm cultures (80% at 1 month, 50% at 2 months). Several mechanisms could account for this gradual decrease in ␤-gal-positive cells in vitro. The C17.NT-3 clone may contain untransduced C17 cells that outgrew C17.NT-3 cells. This is unlikely to be the only reason, however, because it would require that untransduced C17 cells grow much faster than C17.NT-3 cells, and we observed that C17.NT-3 cells grow roughly at the same speed as C17 cells. Other possibilities include promoter downregulation, gene inactivation, loss of either or both transgenes, and/or a bias introduced by the IRES sequence.
In contrast, transgene expression in vivo was variable. One week following transplantation, most of the cells in the center of the graft were not stained by either X-gal histochemistry or ␤-gal immunocytochemistry (Figs. 7C and 7E ), although the majority appeared to be donor derived since their morphology was the same as the X-gal/␤-gal-positive cells on the periphery of the graft (Figs. 7A-7C) . The host immune reaction may have been a major contributor to the loss of transgene expression in vivo since OX-42-positive cells were observed in the center of the graft (Fig. 11A) . Promoter downregulation may also account for the decrease of X-gal/␤-gal-positive cells in grafts with longer survival. Despite downregulation of the LTR promoter, the IRES functioned well in vivo, since a majority of X-galpositive cells were also stained by anti-NT-3 antibodies (Figs. 7F and 7G) .
In Vitro and in Vivo Differentiation of the C17.NT-3 Cells
Under conditions of active cell division, most C17.NT-3 cells remained undifferentiated in vitro (Fig. 5 ). This contrasted with observations of another NT-3-expressing subclone of C17 (C17.2.NT-3) in which NT-3 production accelerated differentiation in vitro, typically to an overwhelmingly neuronal phenotype, even on uncoated dishes, and concomitantly halted or dramatically diminished proliferation ( Fig. 6; 44) . NT-3 expression therefore did not influence the differentiation of C17.NT-3 cells whereas it induced C17.2.NT-3 cells to differentiate into neurons through an autocrine/paracrine mechanism (1). C17.2.NT-3 neural stem cells have been shown to express and signal intracellularly through Trk C, the high-affinity receptor for NT-3, and to differentiate into cholinergic, GABAergic, and glutamatergic neurons (46) . Trk C expression in C17.NT-3 cells has not been studied, but is unlikely because their response to NT-3 differed from that of the C17.2.NT-3 cells. The phenotypic difference between C17.NT-3 and C17.2.NT-3 cells that we observed in vitro may have resulted from differences in retroviral insertion sites in the two subclones of the neural stem cells or different levels of Trk C expression.
Many C17.NT-3 cells surviving as xenografts in adult host spinal cord appeared morphologically to be differentiated (Fig. 8) , consistent with previous reports of these and other progenitor cells. For example, C17.2 cells transplanted into neonatal cerebellum have been shown to differentiate into neurons or glia in a cytoarchitecturally appropriate manner (55) and to replace apoptotic pyramidal neurons in the adult neocortex (60) . Other cell lines, such as the Raphe-derived neuronal progenitor cell line RN33B (67) , have also been shown to undergo site-specific morphological differentiation when allografted into brain or spinal cord of adult Sprague-Dawley rats (44, 53) . These observations suggest that the adult CNS environment can provide appropriate cues to direct the differentiation of neural progenitor and stem cells (44, 53, 57, 60) . The morphological differentiation of xenografted C17.NT-3 cells in spinal cord was remarkably similar to that of allografted RN33B cells (44) , suggesting that the environmental cues that guide differentiation and the mechanisms by which neural progenitor and stem cells respond to these cues are conserved across species and among progenitor or precursor cells isolated from different CNS regions.
The fact that C17.NT-3 cells differentiated into neurons and glia in vivo (Figs. 8 and 9 ) but not in vitro (Fig.  5 ) emphasizes the importance of the environmental signals provided by the host spinal cord. C17.NT-3 cells engrafted into the host spinal cord shared phenotypic characteristics, including MAP1B and MAP2 expression, with cultured C17.2.NT-3 cells which are known to mediate NT-3 intracellular signaling appropriately via Trk C (46) . We speculate that signals (such as growth factors) from the host spinal cord may have stimulated expression of Trk C on C17.NT-3 cells, which then responded in a fashion similar to C17.2.NT-3 cells.
Survival of Intraspinal Grafted C17.NT-3 Cells in a Cross-Species Host
Despite the orally administered immune suppression, the survival of xenografted C17.NT-3 cells in spinal cord was poorer than allografted C17.2 cells in brain (55) . Unlike allografted fibroblasts (29) , the size of C17.NT-3 grafts and the total number of X-gal/␤-galpositive cells decreased with time. One explanation for the relatively poor and variable graft survival may have been an adult rat host immune response against donor murine cells and/or transgene product as a result of differences in preparations of CsA oral solution or the amount ingested. Effective immunosuppression is crucial for the survival of the donor cells (9, 10, 17, 23) and can be achieved by parenteral CsA (Liu et al., unpublished) . Individual hosts or transplant procedures may vary, however, since survival varied even when C17.2 cells were allografted into littermates (55) .
Summary
In the present study we have constructed a stable NT-3-expressing clone of engraftable murine neural stem cells (C17.NT-3) and characterized their survival, differentiation, and transgene expression in vitro and as intraspinal xenografts into adult rats. The results support the idea that genetically engineered neural progenitor or stem cells expressing neurotrophins may one day be applied to SCI.
